TERE1 Inhibitors

TERE1 Inhibitors encompass a range of compounds that interact with or influence the activity of the UbiA prenyltransferase domain-containing protein 1 (TERE1). These inhibitors are not directly targeting TERE1; rather, they influence the biochemical pathways and processes in which TERE1 is involved. The primary mechanism of action for these inhibitors is the disruption or modification of the prenylation process, a post-translational modification essential for the function of several proteins, including TERE1.

This class includes inhibitors of farnesyltransferase and geranylgeranyltransferase, such as GGTI-298 and FTI-277, which prevent the addition of farnesyl and geranylgeranyl groups to proteins. By inhibiting these enzymes, the inhibitors indirectly affect the activity of proteins that require prenylation for their function or localization, which could include TERE1. Additionally, compounds like Lovastatin, Simvastatin, and Atorvastatin, known for their role in inhibiting HMG-CoA reductase, are part of this class. These statins reduce the availability of isoprenoid intermediates necessary for prenylation, thereby reducing the substrate pool available for TERE1-mediated prenylation. Moreover, this class includes inhibitors of squalene synthase, which play a role in cholesterol biosynthesis. By inhibiting this enzyme, these compounds can indirectly influence the availability of precursors necessary for the prenylation process. Compounds such as Zoledronic Acid, Alendronate, Risedronate, and Ibandronate, which inhibit farnesyl diphosphate synthase, also fall under the umbrella of TERE1 inhibitors. By impeding the synthesis of farnesyl diphosphate, a key precursor for prenylation, these compounds can modulate the prenylation pathway, thereby affecting proteins associated with this process.